Epirubicin, Oxaliplatin, and Capecitabine Regimen for Gastric and Esophageal Cancer-Reference-Cited by-同舟云学术

Epirubicin, Oxaliplatin, and Capecitabine Regimen for Gastric and Esophageal Cancer

Published:2011-09 Issue:9 Volume:46 Page:657-663
ISSN:0018-5787
Container-title:Hospital Pharmacy
language:en
Short-container-title:Hosp Pharm

Author:

Waddell J. Aubrey¹,Solimando Dominic A.²

Affiliation:

1. University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804

2. Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Pharmacology,Pharmacy

Link

http://journals.sagepub.com/doi/pdf/10.1310/hpj4609-657

Reference23 articles.

1. Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer

2. Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer

3. A Phase II Trial of Epirubicin, Oxaliplatin, and Capecitabine (EOX) as First-Line Chemotherapy in Advanced Gastric Cancer: A Chinese Single-Center Experience

4. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

5. Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial